氧气驱动雾化吸入盐酸氨溴索治疗小儿肺炎的效果观察

Observation on the effect of oxygen-driven atomizing inhalation of ambroxol hydrochloride in the treatment of pediatric pneumonia

目的探究氧气驱动雾化吸入盐酸氨溴索治疗小儿肺炎的效果。方法 56例小儿肺炎患儿,查病例号按照奇偶数将其分为对照组和实验组,每组28例。对照组采用常规治疗,实验组在对照组的基础上采用氧气驱动雾化吸入盐酸氨溴索治疗。比较两组患儿的治疗效果,咳嗽、咯痰、肺部啰音消失时间及不良反应发生情况。结果实验组患儿的治疗总有效率为92.86%,高于对照组的71.43%,差异具有统计学意义(P<0.05)。实验组患儿的咳嗽消失时间(7.26±2.56)d、咯痰消失时间(6.13±1.52)d、肺部啰音消失时间(3.36±1.12)d均短于对照组的(9.33±2.52)、(8.95±2.46)、(6.62±2.42)d,差异均具有统计学意义(P<0.05)。实验组不良反应发生率低于对照组,差异具有统计学意义(X^2=6.7200, P=0.0095<0.05)。结论对小儿肺炎患儿采用氧气驱动雾化吸入盐酸氨溴索治疗,可明显提升患儿的治疗效果,缩短咳嗽、咯痰、肺部啰音消失时间,减少不良反应,值得临床深究。

Objective To investigate the effect of oxygen-driven atomizing inhalation of ambroxol hydrochloride in the treatment of pediatric pneumonia. Methods A total of 56 pneumonia children were divided by odd and even case number into control group and experimental group, with 28 cases in each group. The control group received conventional therapy, and the experimental group received oxygen-driven atomizing inhalation of ambroxol hydrochloride on the basis of the control group. Comparison were made on treatment effect, disappearance time of cough, sputum and pulmonary rales and occurrence of adverse reactions between the two groups. Results The experimental group had higher total treatment effective rate as 92.86% than 71.43% in the control group, and the difference was statistically significant(P<0.05). The experimental group had shorter cough disappearance time as(7.26±2.56) d, sputum disappearance time as(6.13±1.52) d and disappearance time of pulmonary rales as(3.36±1.12) d than(9.33±2.52),(8.95±2.46) and(6.62±2.42) d in the control group. Their difference was statistically significant(P<0.05). The experimental group had lower incidence of adverse reactions than the control group, and the difference was statistically significant(X^2=6.7200, P=0.0095<0.05). Conclusion Oxygen-driven atomizing inhalation of ambroxol hydrochloride for pediatric pneumonia can obviously improve the treatment effect, shorten disappearance time of cough, sputum and pulmonary rales, and reduce the adverse reactions. It is worthy of further clinical study.